Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
Chiwoo Oh, Postdoctoral Research Fellow at Harvard Medical School, shared a post on LinkedIn about recent article by Fabiana Corsi-Zuelli et al, published in Nature Medicine, adding:
“The AS01B adjuvant (MPL plus QS 21) in Shingrix initially induces strong innate immune activation but subsequently causes long term reprogramming of the chromatin and transcriptional state of monocytes, reducing inflammatory cytokine responses such as IL6 upon subsequent TLR stimulation.
This may, in turn, decrease chronic vascular and atherosclerosis-associated inflammation, potentially lowering the risk of cardiovascular events.”
Title: Recombinant shingles vaccination and the risk of cardiovascular events
Authors: Fabiana Corsi-Zuelli, Fang Li, Rachel Upthegrove, John A. Todd, Betty Raman, Paul J. Harrison, Maxime Taquet
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron
-
Sep 3, 2026, 16:54Ralf Ludwig։ Testing Human-Targeted Therapies in a Human Immune System
-
Sep 3, 2026, 16:35Mohsen Salimi: Non-Contrast Chest CT as a Biomarker for Mild-to-Moderate Anemia
-
Sep 3, 2026, 16:10Tanzeel Alamin Almahdi Gorashi: NLR as an Accessible Biomarker for Monitoring Pediatric Sickle Cell Anemia
-
Sep 3, 2026, 15:42Manuel De Jesus: Innovating Anemia Monitoring Through Biomedical Engineering and Digital Technology
-
Sep 3, 2026, 15:37Hadis Nabipoor: QICL2026 Highlights the Critical Importance of Transfusion Safety
-
Sep 3, 2026, 15:32Gopal Patidar: The ISBT Haemovigilance Working Party Sharing Knowledge and Promoting Best Practices